Background: Epilepsy is the most prevalent chronic neurological disorder in childhood, yet optimal antiseizure medication (ASM) selection in resource-limited pediatric settings remains incompletely characterized. Objective: To evaluate ASM prescribing patterns and six-month seizure outcomes among children with epilepsy managed at Fergana Regional Multidisciplinary Children's Hospital. Methods: A retrospective cross-sectional study was conducted on 78 patients under 18 years of age diagnosed with epilepsy. Data on ASM regimen, seizure frequency, EEG findings, and adverse events were extracted from medical records and analyzed. Results: Levetiracetam monotherapy achieved seizure freedom in 58.3% of patients, outperforming valproate monotherapy (52.6%), while dual VPA+LEV therapy showed the highest seizure-free rate (68.4%). Adverse events were more frequent with dual-therapy regimens. EEG normalisation occurred in 37-47% of patients across groups. Conclusion: Levetiracetam demonstrates favorable efficacy and tolerability as monotherapy in pediatric epilepsy in the Fergana region. Dual therapy confers modest additional seizure control at the cost of higher adverse event rates.
Publication Date: 2026-06-05